(RTTNews) - The U.S. Food and Drug Administration granted de novo marketing authorization for Invitae's Common Hereditary Cancers Panel, an in vitro diagnostic test to help detect dozens of cancer ...
SAN FRANCISCO, Dec. 20, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it has completed a transaction with Integrated DNA Technologies, Inc. (IDT), ...
— The transaction contributes to Invitae's cash runway and includes a strategic supply partnership to support the growth of Invitae Personalized Cancer Monitoring™ (PCM) services — SAN FRANCISCO, Dec.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback